Allurion TechnologiesALUR
ALUR
About: Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Employees: 137
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.79% more ownership
Funds ownership: 22.61% [Q4 2024] → 23.39% (+0.79%) [Q1 2025]
4% less funds holding
Funds holding: 25 [Q4 2024] → 24 (-1) [Q1 2025]
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
29% less capital invested
Capital invested by funds: $6.3M [Q4 2024] → $4.44M (-$1.86M) [Q1 2025]
93% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 14
100% less funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 0 (-1) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for ALUR.
Financial journalist opinion
Based on 3 articles about ALUR published over the past 30 days
Neutral
Business Wire
2 days ago
Allurion Announces Strategic Distribution Partnership with Minogue Medical in Canada to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced a strategic distribution partnership with Minogue Medical Inc., a leading Canadian medical device company specializing in bariatric and obesity care. This new partnership draws upon Minogue Medical's 40-year experience in the Canadian market and reflects Allurion's commitment to establishing a new standard of care in obesity management focused on metabolicall.
Neutral
Business Wire
4 days ago
Allurion Announces Submission of PMA to FDA and Additional Analyses From Pivotal AUDACITY Study That Meet Both Endpoints
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced submission of the fourth and final module of the Pre-Market Approval (PMA) application to the Food & Drug Administration (FDA) and additional, supportive analyses from the AUDACITY Study that meet both of the pre-specified co-primary endpoints. Topline results announced previously showed that the AUDACITY Study met its first co-primary endpoint related to.
Neutral
Business Wire
3 weeks ago
Allurion Announces Findings from New Studies on Muscle Mass Maintenance in Nearly 20,000 Patients and Four-Year Weight Loss Outcomes at the 2025 Annual Meeting of the ASMBS
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today presented two new abstracts at the American Society for Metabolic & Bariatric Surgery (ASMBS) 2025 Annual Meeting. This data include findings from a global, real-world experience evaluating body composition outcomes that demonstrate sustained weight loss, significant fat loss, and preservation of muscle mass with the Allurion Program and one of the longest real-wor.
Neutral
Business Wire
1 month ago
Allurion to Present at Jefferies Global Healthcare Conference
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced that Dr. Shantanu Gaur, Founder and Chief Executive Officer, will present at the upcoming Jefferies Global Healthcare Conference in New York. The live presentation will take place on Wednesday, June 4 at 3:45 p.m. ET. A webcast of the presentation will be available in the Events & Presentations section of Allurion's investor.
Neutral
Business Wire
1 month ago
Allurion Presents Data on Increasing Muscle Mass and Decreasing Fat Mass in Patients Treated With the Allurion Program
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the presentation of a study at the Societe Francaise et Francophone de Chiurgie de l'Obesite et des Maladies Metaboliques (SOFFCO.MM) meeting in Saint-Etienne, France, May 22-23, 2025. The study, entitled “The Swallowable Gastric Balloon Program with AI Powered Health Coach Leads to Metabolically Healthy Weight Loss in French Pat.
Negative
Zacks Investment Research
1 month ago
4 Medical Product Stocks to Watch From a Challenging Industry
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fundamentals.
Neutral
Seeking Alpha
1 month ago
Allurion Technologies Inc. (ALUR) Q1 2025 Earnings Call Transcript
Allurion Technologies Inc. (NYSE:ALUR ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Tara Brady - Interim CFO Shantanu Gaur - Founder and CEO Conference Call Participants Jason Wittes - ROTH Capital Partners Josh Jennings - TD Cowen Keay Nakae - Chardan Capital Mike Toomey - Jefferies Operator Hello, everyone, and welcome to Allurion First Quarter Earnings Call. All lines have been placed on mute to prevent any background noise.
Positive
Zacks Investment Research
1 month ago
Allurion Technologies, Inc. (ALUR) Q1 Earnings Beat Estimates
Allurion Technologies, Inc. (ALUR) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of a loss of $1.53 per share. This compares to earnings of $2.75 per share a year ago.
Neutral
Business Wire
1 month ago
Allurion Reports First Quarter 2025 Financial Results and Provides Business Update
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (NYSE: ALUR) (“Allurion” or the “Company”), a pioneer in metabolically healthy weight loss, today announced its financial results for the first quarter and provided a business update. Recent Company Highlights and Outlook Maintaining 2025 revenue guidance of approximately $30 million with a reduction of approximately 50% in operating expenses compared to 2024 First quarter revenue of $5.6 million and operating expenses of $11.4 million.
Neutral
Business Wire
1 month ago
Allurion Presents Data on the Allurion Balloon and AI-Powered Virtual Care Suite with and without GLP-1s to Optimize Muscle Mass and Increase Weight Loss
NATICK, Mass.--(BUSINESS WIRE)---- $ALUR--Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the presentation of four abstracts at the European Congress on Obesity (ECO) taking place in Malaga, Spain, May 11-14, 2025. These studies highlight the transformative impact of the Allurion Balloon and the Virtual Care Suite (VCS)—the AI-powered digital platform that includes Coach Iris—on weight loss outcomes and lean body mass.
Charts implemented using Lightweight Charts™